| An update on the biology and management of dyskeratosis congenita and related telomere biology disorders |
19 |
| High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review |
15 |
| Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia |
14 |
| Disseminated intravascular coagulation: an update on pathogenesis and diagnosis |
12 |
| Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy |
11 |
| The benefits of prophylaxis in patients with hemophilia B |
10 |
| Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? |
10 |
| Novel targets for the treatment of relapsing multiple myeloma |
9 |
| Ferumoxytol for the treatment of iron deficiency anemia |
9 |
| The potential role of miRNAs in multiple myeloma therapy |
9 |
| Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy |
9 |
| An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura |
8 |
| Anticoagulation at the extremes of body weight: choices and dosing |
7 |
| A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia |
7 |
| The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts |
7 |
| The value of HEAD-US system in detecting subclinical abnormalities in joints of patients with hemophilia |
7 |
| Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy |
7 |
| Stem cell transplantation in sickle cell disease: therapeutic potential and challenges faced |
7 |
| CXCR4 mutations affect presentation and outcomes in patients with Waldenstrom macroglobulinemia: A systematic review |
7 |
| Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia |
6 |
| The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe |
6 |
| Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges |
6 |
| Impact and management of iron deficiency and iron deficiency anemia in women's health |
6 |
| Thrombophilia, risk factors and prevention |
5 |
| Overcoming challenges of venous thromboembolism in sickle cell disease treatment |
5 |
| Getting personal with myelodysplastic syndromes: is now the right time? |
5 |
| Autoimmune cytopenias in chronic lymphocytic leukemia: a concise review and treatment recommendations |
5 |
| Venetoclax for the treatment of multiple myeloma |
5 |
| Use of acalabrutinib in patients with mantle cell lymphoma |
5 |
| Trisomy 8 in acute myeloid leukemia |
5 |
| A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease |
5 |
| Regulatory role of thiol isomerases in thrombus formation |
5 |
| A concise review of BCL-2 inhibition in acute myeloid leukemia |
5 |
| The importance of inhibitor eradication in clinically complicated hemophilia A patients |
5 |
| Potential of NK cells in multiple Myeloma therapy |
5 |
| Genetic profiling in acute myeloid leukemia: a path to predicting treatment outcome |
5 |
| Health-related quality of life in adult primary immune thrombocytopenia |
4 |
| Healthcare expenses for treatment of acute myeloid leukemia |
4 |
| Considering the spleen in sickle cell disease |
4 |
| Hematopoietic stem cell transplant with HLA-mismatched grafts: impact of donor, source, conditioning, and graft versus host disease prophylaxis |
4 |
| Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia |
4 |
| Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment |
4 |
| GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy |
4 |
| Management of antithrombin deficiency: an update for clinicians |
4 |
| The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications |
4 |
| Prognostic factors for multiple myeloma in the era of novel therapies |
4 |
| Considerations when restarting anticoagulants in patients with atrial fibrillation after bleeding |
4 |
| Non-Hodgkin's lymphoma of the oral cavity and maxillofacial region: a pathologist viewpoint |
4 |
| Updates on thrombotic events associated with multiple myeloma |
4 |
| Novel therapies in low- and high-risk myelodysplastic syndrome |
4 |
